Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia.
about
Targeting LKB1 in cancer - exposing and exploiting vulnerabilitiesOncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cellsIntegrated methylome and transcriptome analysis reveals novel regulatory elements in pediatric acute lymphoblastic leukemia.MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cellsA genome landscape of SRSF3-regulated splicing events and gene expression in human osteosarcoma U2OS cells.Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in gastric cancer.T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies.Maternal embryonic leucine zipper kinase inhibits epithelial-mesenchymal transition by regulating transforming growth factor-β signaling.Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.Targeting Programmed Cell Death Using Small-Molecule Compounds to Improve Potential Cancer Therapy.p53-independent p21 induction by MELK inhibition.Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials.TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancerMELK is a novel therapeutic target in high-risk neuroblastoma.Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma.Identification of potential therapeutic targets in prostate cancer through a cross-species approach.Challenges in validating candidate therapeutic targets in cancer.
P2860
Q26801412-C7993B08-DF8A-4FD2-B53A-B317E08F7A6CQ35942699-13EA80E9-C969-43DA-BFF6-0880638CAEE7Q36213492-D4A3DF2D-7647-4898-9B05-3155FD7C6859Q36275700-73A79F46-FF0D-4786-BA32-A9E1F2F1AF68Q36627944-A393A8D0-0ED6-454B-8577-3AA5B718600EQ36905898-F4510FB2-A680-45CE-B723-BE1CD23965B8Q38261327-E74219CA-B092-4641-8D66-910637DA36FEQ38648606-EA50A97D-E897-4C10-B4AD-9EAD09FF63EAQ38701009-41665835-9A8F-4769-9F35-623274BF5250Q38790859-42E898F9-3CA3-4A2C-8401-33DB03F785F6Q38881119-3AAD255A-229A-4953-8EAA-7CA479D02074Q41709133-A29AE031-F48E-4E65-AEA0-E1CDAFFBF44DQ41900139-56BD794A-E586-4B63-B063-D75A797246AEQ42108657-7CF342C4-3E0B-4FDE-9D93-D8E476285156Q42292977-5996B535-9EB2-42CB-B743-489D70F6F446Q49187608-F541DA6C-D19C-486B-9BE9-7FFB3DDAE04AQ49869942-AF87C09A-E04C-4AFC-AF4D-6C82522D7045Q50043890-D1BB7591-62A4-454C-8411-E7E737F7705FQ50123858-7FB53D38-AC45-4B4A-8A78-D4CC71E6935A
P2860
Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Preclinical efficacy of matern ...... ion in acute myeloid leukemia.
@ast
Preclinical efficacy of matern ...... ion in acute myeloid leukemia.
@en
type
label
Preclinical efficacy of matern ...... ion in acute myeloid leukemia.
@ast
Preclinical efficacy of matern ...... ion in acute myeloid leukemia.
@en
prefLabel
Preclinical efficacy of matern ...... ion in acute myeloid leukemia.
@ast
Preclinical efficacy of matern ...... ion in acute myeloid leukemia.
@en
P2093
P2860
P50
P356
P1433
P1476
Preclinical efficacy of matern ...... tion in acute myeloid leukemia
@en
P2093
Gregory Malnassy
Karsten Spiekermann
Martin B G Mutonga
Noreen Fulton
Stefan K Bohlander
Wendy Stock
Wolfgang Hiddemann
Yusuke Nakamura
P2860
P304
12371-12382
P356
10.18632/ONCOTARGET.2642
P407
P577
2014-12-01T00:00:00Z